Industry News
Investigational immunotherapy drug well tolerated in those with rare form of melanoma
6/08/2016
An investigational immunotherapy drug being tested in the treatment of a rare form of skin cancer known as Merkel cell carcinoma has been found to be well tolerated with a clinical benefit seen in...
New approach to MRI links saturated fats to breast cancer in postmenopausal women
6/08/2016
The presence of high saturated fatty acids in breast tissue may be a useful indicator of cancer in postmenopausal women, according to a new study by researchers at NYU Langone Medical Center...
A shorter 4-week radiation regimen is non-inferior to the standard 8-week regimen when it comes to prostate cancer treatment, an Ontario-led study has found.
New approach could make bone marrow transplants safer
6/08/2016
Harvard Stem Cell Institute (HSCI) scientists have taken the first steps toward developing a treatment that would make bone marrow - blood stem cell - transplantation safer and, as a result, more...
Blood-born molecules could predict those who will develop liver cancer
6/07/2016
A panel of microRNAs from blood samples may predict patients at high risk of developing a common liver cancer from hepatitis B virus infection.
Pembrolizumab elicits significant antitumor activity in head and neck cancer patients
6/07/2016
Treating head and neck cancer patients with recurrent or metastatic disease with the PD-1 inhibitor pembrolizumab resulted in significant clinical responses in a fifth of the patients from a phase...
Study may help reassure women taking tamoxifen for breast cancer
6/07/2016
A study led by Loyola Medicine researchers may help reassure patients who worry the breast cancer drug tamoxifen could increase their risk of uterine cancer.
Methotrexate exposure impacts cognitive processes cancer survivors need to multitask
6/07/2016
Research from St. Jude Children's Research Hospital suggests that pediatric leukemia patients exposed to higher concentrations of the chemotherapy drug methotrexate are more likely to struggle with...
Bristol-Myers Squibb has announced the latest long-term overall survival (OS) results from two dose-ranging Phase I and Phase II studies, CA209-003 and CA209-010, which evaluated nivolumab in...
Lenalidomide maintenance therapy improves overall survival for patients with multiple myeloma
6/07/2016
While several clinical trials have demonstrated that maintenance therapy with lenalidomide reduces the risk of disease progression in patients with multiple myeloma, there have been no definitive...